[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endophthalmitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endophthalmitis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,70,93,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100467906","nanopore-sequencing-in-ophthalmology-100467906",false,"NCT05372861","Nanopore Sequencing in Ophthalmology","Nanopore Sequencing in Ophthalmology - a Paradigm Shift in Pathogen Determination?","Inclusion Criteria:\n\n* Eyes of patients with endophthalmitis\n\nExclusion Criteria:\n\n* No informed consent possible\n* Participation in other studies","ALL","18 Years","99 Years",{"count":20,"type":21},20,"ESTIMATED","OBSERVATIONAL","In this pilot study, the feasibility of the Oxford Nanopore MinION to identify pathogens from vitrectomy samples in eyes with endophthalmitis shall be assessed. The MinION is a low cost commercially available device for DNA\u002F RNA analysis that, in studies, has been used for pathogen determination in various infectious diseases as well as for the genetic characterization of hematologic tumors.",[25],"Endophthalmitis",[25,27,28],"Nanopore sequencing","Next Generation Sequencing","RECRUITING","2025-09-29",{"date":32,"type":33},"2025-09-30","ACTUAL",{"date":35,"type":33},"2022-04-22",{"date":37,"type":21},"2027-12-01",{"name":39,"class":40},"Medical University of Graz","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100304506","phase-2-safety-and-efficacy-of-intracameral-zimoxin-for-prevention-of-endophthalmitis-after-cataract-surgery-100304506","NCT03244072","Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery","Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery","Inclusion Criteria:\n\n* visually significant cataracts\n\nExclusion Criteria:\n\n* allergy to fluoroquinolones, cobalamin (B12)",true,"40 Years",{"count":52,"type":21},60000,"INTERVENTIONAL",[55,56],"PHASE2","PHASE3","Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis",[25],"NOT_YET_RECRUITING","2025-09-21",{"date":62,"type":33},"2025-09-25",{"date":64,"type":21},"2026-06-01",{"date":66,"type":21},"2031-10",{"name":68,"class":69},"Jason Ahee, M.D.","INDUSTRY",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":78,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":41},"100606419","vascular-changes-associated-with-endophthalmitis-100606419","NCT07175311","Vascular Changes Associated With Endophthalmitis.","Inclusion Criteria:\n\n* Patients with a history of endophthalmitis Diagnosis of Endophthalmitis\n* Clinical symptoms: Pain, decrease in visual acuity, anterior chamber cells and\u002For vitreous turbidity, corneal edema, conjunctival hyperemia\n* Laboratory studies: B-mode USG and or positive culture\n* Patients who meet the endophthalmitis resolution criteria of the Mexican Endophthalmitis Study Group\n* Patients with previously signed informed consent\n\nExclusion Criteria:\n\n* Patients who have not signed the informed consent\n* Patients under 18 years.\n* Patients with endophthalmitis who do not meet the resolution criteria of the Mexican Endophthalmitis Study Group",{"count":77,"type":21},71,"6 Weeks","This study aims to describe and investigate vascular changes associated with exogenous endophthalmitis, as well as to create a photo library where they are evidenced",[25],[82,83],"Postoperative endophthalmitis","Multimodal imaging","2025-09-09",{"date":86,"type":33},"2025-09-16",{"date":88,"type":33},"2024-11-01",{"date":90,"type":21},"2026-03-01",{"name":92,"class":40},"Asociación para Evitar la Ceguera en México",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":41},"100472473","complex-ocular-infection-optimization-of-microbiological-diagnosis-100472473","NCT05432336","Complex Ocular Infection, Optimization of Microbiological Diagnosis","ICODIA","Inclusion Criteria:\n\n* Adult patient\n* Patient presenting or having presented a clinical suspicion of complex ocular infection requiring a sample for microbiological diagnosis:\n\n  * Corneal abscess requiring hospitalization\n  * Any suspicion of endogenous or exogenous endophthalmitis.\n* Patient not opposed to participating in the research\n\nExclusion Criteria:\n\n* Patient under guardianship or curatorship\n* Pregnant women",{"count":101,"type":21},153,"The purpose of this study is to evaluate the impact of different technique to optimize the microbiological diagnosis of the COI.\n\n* Metagenomic for the endophtalmitis\n* Multiplex polymerase chain reaction for corneal abscesses",[25,104],"Keratitis",[106,107,108,109,110],"Endogenous Endophtalmitis","exogenous endophtalmitis","keratitis","PCR","NGS","2025-09-08",{"date":113,"type":33},"2025-09-15",{"date":115,"type":33},"2023-11-21",{"date":117,"type":21},"2026-01",{"name":119,"class":40},"Assistance Publique - Hôpitaux de Paris",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100567868","evaluation-and-risk-factors-of-post-traumatic-endophthalmitis-100567868","NCT06673784","Evaluation and Risk Factors of Post-traumatic Endophthalmitis","Inclusion Criteria:\n\n* Patients exposed to eye trauma and developed post-traumatic endophthalmitis\n\nExclusion Criteria:\n\n* Patients who refuse to sign informed consent in this study",{"count":127,"type":21},41,"1. identify the incidence of post-traumatic endophthalmitis and the related risk factors influencing its development.\n2. study the clinical- microbiological profile and evaluate the functional and anatomical outcomes of post-traumatic endophthalmitis (PPTE).",[25],"2024-11-02",{"date":132,"type":33},"2024-11-05",{"date":134,"type":21},"2024-11-10",{"date":136,"type":21},"2026-03",{"name":138,"class":40},"Assiut University"]